Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Different D-Dimer Values Compared for Venous Thromboembolism Risk

By LabMedica International staff writers
Posted on 27 Sep 2015
D-dimer assays are generally evaluated according to cutoff points calibrated for of venous thromboembolism (VTE) exclusion and used to estimate the individual risk of recurrence after a first idiopathic event VTE.

The increase in age-dependent D-dimer levels has long been seen as a problem for the use of these assays in the work-up for VTE exclusion, and the assays performs poorly in the elderly population when traditional cutoff levels are adopted. More...
Different cutoff systems have therefore been proposed and prospectively investigated to rule out pulmonary embolism.

Scientist at the University Hospital of Bologna (Italy) and their colleagues screened a total of 1,010 patients, whose index VTE event was idiopathic or associated with weak risk factors, and were included in the management protocol. Persistently negative D-dimer results were recorded in 528 patients (52.8%) who permanently interrupted anticoagulation and were followed up for a maximum of two years. In contrast, the remaining 482 patients had positive D-dimer results, and at the moment of their first positive result, were recommended to continue or resume anticoagulant therapy and followed by their anticoagulation clinic.

D-dimer levels were measured using the following commercial quantitative assays: VIDAS D-dimer Exclusion (bioMerieux; Lyon, France), Innovance D-DIMER (Siemens; Deerfield, IL, USA), HemosIL D-dimer HS or HemosIL D-dimer (Instrumentation Laboratory; Milan, Italy), and (v) STA Liatest D-dimer (DiagnosticaStago; Asnieres-sur-Seine, France). As cutoff values for negative/positive results, the centers used those specific for the assay, distinguishing those with results expressed as fibrinogen equivalent units (FEU) or non-FEU (D-dimer units) and for age and gender.

The predetermined cutoff levels for each assay, specific for age (lower in subjects less than 70 years), and gender (because it is lower in males), were used. In young subjects, the D-dimer-ULtrasonography in Combination Italian Study (DULCIS) low cutoff levels resulted in half the recurrent events that would have occurred using the other criteria. In elderly patients the DULCIS results were similar to those calculated for the two age-adjusted criteria. The adoption of traditional VTE exclusion criteria would have led to positive results in the large majority of elderly subjects without a significant reduction in the rate of recurrent event.

The authors concluded that the low cutoff levels adopted in the DULCIS study for young subjects resulted in more young patients who resumed anticoagulation with subsequent increased protection from recurrent events in this population that is at high risk of recurrence. In elderly patients, the high DULCIS cutoff points led to results similar to those calculated for the two age-adjusted criteria; the adoption of VTE exclusion criteria would have led to positive results in the large majority of subjects, without a significant reduction in the rate of recurrent event. The study was published on September 12, 2015, in the journal International Journal of Laboratory Hematology.

Related Links:

University Hospital of Bologna
bioMérieux
Siemens



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.